Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Federal Trade Commission
Harvard Business School
Fuji
Farmers Insurance
Colorcon
Cipla
Dow
AstraZeneca

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,500,434

« Back to Dashboard

Title: Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs
Abstract:The invention relates to combinations of angiotensin-converting enzyme inhibitors with calcium antagonists, processes for their preparation and their use as medicaments.
Inventor(s): Becker; Reinhard (Wiesbaden, DE), Henning: Rainer (Hattersheim am Main, DE), Ruger; Wolfgang (Kelkheim, DE), Teetz; Volker (Hofheim am Taunus, DE), Urbach; Hansjorg (Kronberg/Taunus, DE)
Assignee: Hoechst Aktiengesellschaft (Frankfurt am Main, DE)
Filing Date:Apr 11, 1994
Application Number:08/225,762
Claims:1. A pharmaceutical composition, comprising a) 1-[N-(1-S-1-[N-(1-S-ethoxycarbonyl-3-phenylpropyl)-S-alanyl]-(2S,3aR,7aS)- octahydro[1H]indole-2-S-carboxylic acid (trandolapril) or a physiologically acceptable salt thereof in combination with b) 4-(2,3-dichlorophenyl)-2,6-dimethyl-3-methoxycarbonyl-5-ethoxycarbonyl-1,4 -dihydropyridine (felodine) or a physiologically acceptable salt thereof, wherein a) and b) are present in a combined amount more effective to lower blood pressure than the individual amounts of either a) or b) administered separately.

2. A method for the treatment of high blood pressure, which comprises administering to a host in recognized need thereof an effective amount of a pharmaceutical composition as claimed in claim 1.

3. A method for the treatment of cardiac insufficiency, which comprises administering to a host in recognized need thereof an effective amount of a pharmaceutical composition as claimed in claim 1.

4. A method for the treatment of coronary heart disease, which comprises administering to a host in recognized need thereof an effective amount of a pharmaceutical composition as claimed in claim 1.

5. A pharmaceutical composition as claimed in claim 1, wherein said composition comprises a physiologically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Julphar
Dow
Chinese Patent Office
Moodys
Argus Health
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.